A comparison of whole-body MRI and CT for the staging of lymphoma.

OBJECTIVE Our objective was to compare whole-body MRI and CT for the staging of lymphoma. CONCLUSION Whole-body MRI represents an alternative to CT in the staging of lymphoma, with an ability to stage disease, identify lymph nodes greater than 1.2 cm, and the additional ability to evaluate for the presence or absence of disease spread to bone marrow. CT allows detection of more nodes (< 1.2 cm) than MRI but this does not alter tumor stage.

[1]  M. Taupitz,et al.  Local staging of rectal cancer: the current role of MRI , 2006, European Radiology.

[2]  Thomas F Hany,et al.  Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT? , 2004, Radiology.

[3]  David J Brenner,et al.  Estimated radiation risks potentially associated with full-body CT screening. , 2004, Radiology.

[4]  M. Baccarani,et al.  Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients , 2004, British Journal of Cancer.

[5]  P. Gaulard,et al.  Bone marrow with diffuse tumor infiltration in patients with lymphoproliferative diseases: dynamic gadolinium-enhanced MR imaging. , 2003, Radiology.

[6]  M. O'Doherty,et al.  Limitations of PET for imaging lymphoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  J. Biederer,et al.  Simulated pulmonary nodules implanted in a dedicated porcine chest phantom: sensitivity of MR imaging for detection. , 2003, Radiology.

[8]  Jürgen Biederer,et al.  Lung morphology: fast MR imaging assessment with a volumetric interpolated breath-hold technique: initial experience with patients. , 2003, Radiology.

[9]  F. Schick,et al.  [Imaging diagnosis of solitary pulmonary nodules on an open low-field MRI system--comparison of two MR sequences with spiral CT]. , 2002, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[10]  M. Schwaiger,et al.  PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  E. Rummeny,et al.  Iron-oxide-enhanced MR imaging of bone marrow in patients with non-Hodgkin's lymphoma: differentiation between tumor infiltration and hypercellular bone marrow , 2002, European Radiology.

[12]  O. Schober,et al.  Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. , 2001, AJR. American journal of roentgenology.

[13]  R. Hustinx,et al.  Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  B. Cheson,et al.  Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  H. Curtin,et al.  Imaging-based nodal classification for evaluation of neck metastatic adenopathy. , 2000, AJR. American journal of roentgenology.

[16]  G. Demir,et al.  Magnetic resonance imaging of bone marrow versus bone marrow biopsy in malignant lymphoma , 1999, Pathology & Oncology Research.

[17]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Masatoshi Itoh,et al.  Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-d- glucose using whole-body positron emission tomography and magnetic resonance imaging , 1998, European Journal of Nuclear Medicine.

[19]  Richard L. Wahl,et al.  FDG-PET Determination of Metabolically Active Tumor Volume and Comparison with CT. , 1998, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[20]  E. Melhem,et al.  A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. , 1997, AJR. American journal of roentgenology.

[21]  A. Shields,et al.  Comparison of initial lymphoma staging using computed tomography (CT) and magnetic resonance (MR) imaging , 1994, American journal of hematology.

[22]  M. Hudson,et al.  MR imaging of infradiaphragmatic lymphadenopathy in children and adolescents with Hodgkin disease: Comparison with lymphography and CT , 1993, Journal of magnetic resonance imaging : JMRI.

[23]  S. Hancock,et al.  Breast Cancer After Treatment of Hodgkin's Disease , 1993 .

[24]  S. Hancock,et al.  Thyroid diseases after treatment of Hodgkin's disease. , 1991, The New England journal of medicine.

[25]  A. Shields,et al.  Detection of lymphomatous bone marrow involvement with magnetic resonance imaging. , 1991, Blood.

[26]  R W Parkey,et al.  Fast short-tau inversion-recovery MR imaging. , 1991, Radiology.

[27]  H. Döhner,et al.  Magnetic resonance imaging of bone marrow in lymphoproliferative disorders: correlation with bone marrow biopsy , 1989, British journal of haematology.

[28]  G. Lund,et al.  Computed Tomography of Mediastinal Lymph Nodes , 1985, Acta radiologica: diagnosis.